Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 592 participants.
Also called NCT02884206
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 592 participants
- Sponsor
- Registry
-
NCT02884206 -
2016-001254-17
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Bulgaria, Canada, Croatia, France, Germany, Italy, Lithuania, Netherlands, Poland, Russia, South Korea, Spain, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02884206. Randomized; double masking; primary purpose treatment. Start 2016-11-23 (actual); primary completion 2022-05-16 (actual). Results posted on 2024-08-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
- Acronym
- PERSPECTIVE
- Condition
- Chronic Heart Failure (CHF)
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- Valsartan
- Intervention (Drug)
- Placebo of LCZ696
- Intervention (Drug)
- Placebo of Valsartan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02884206- Content hash
0215804bb3aeb33eb070e5adc54732d4d4747c6b7598283cbd86a11f34bd0873